ABSTRACT
AIM: Assessment of efficiency and safety of enalapril (enap) and its combination with hydrochlorotiaside (enap-N). MATERIALS AND METHODS: 127 patients with mild and moderate blood hypertension entered an open non-comparative multicenter trial. 60 of them received enap (group 1), 67--enap N (group 2). Group 1 patients were given enap for 2 weeks in a dose 10 mg/day. If this dose was not adequate to normalize blood pressure, it was raised to 20-40 mg/day. Patients of group 2 received enap-N one tablet a day for 3 weeks. If the pressure persisted higher than 140/90 mm Hg, the treatment was continued for 3 weeks more in a dose of 2 tablets a day. RESULTS: Blood pressure lowered under 140/90 mm Hg in 40 patients of group 1 (66.7%). Systolic pressure dropped by 10 mm Hg minimum and diastolic by 5 mm minimum in 18 group 1 patients (30%). Enap-N reduced blood pressure under 140-90 mm Hg in 44 of 67 patients (65.7%). Systolic and diastolic pressure dropped, respectively, in 23(34.3%) patients. CONCLUSION: Enap and enap-N tablets were found highly effective and well tolerated. Side effects were caused by lowering of blood pressure.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Enalapril/therapeutic use , Hypertension/drug therapy , Administration, Oral , Adolescent , Adult , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Pressure/drug effects , Diuretics , Drug Therapy, Combination , Enalapril/administration & dosage , Follow-Up Studies , Humans , Hydrochlorothiazide/administration & dosage , Hydrochlorothiazide/therapeutic use , Hypertension/diagnosis , Hypertension/physiopathology , Middle Aged , Safety , Severity of Illness Index , Sodium Chloride Symporter Inhibitors/administration & dosage , Sodium Chloride Symporter Inhibitors/therapeutic use , Treatment OutcomeABSTRACT
A study of the causes of mortality among myocardial infarction patients and of the peculiarities of the manifestations of cardiac decompensation was conducted by way of mathematical prognosing and with the aid of the "Mmirp-1" computer, and permitted to conclude on the necessity of distinguishing between the primary circulatory insufficiency in the acute period, and relapsing circulatory disorders. The prognosis in myocardial infarction permits indirect appraisal of the reserve capacities of the diseased heart. The results of the conducted study indicate that the primary circulatory disorders are 6 times as frequent as the relapsing ones and that half of the patients with signs of circulatory failure dies within the first day of the disease. The long-term prognosis is equally unfavourable for the patients with circulatory insufficiency signs in the acute period: by the end of the 2nd year only 4 of every 10 patients with primary circulatory disorders survive, and 1--2 of every 10 patients with signs of relapsing circulatory disorders, which should be taken into consideration when developing the methods of complex therapy.
